Suppr超能文献

非酒精性脂肪性肝病和动脉高血压,哪个先出现?

Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?

作者信息

Golubeva Julia A, Sheptulina Anna F, Elkina Anastasia Yu, Liusina Ekaterina O, Kiselev Anton R, Drapkina Oxana M

机构信息

Department of Fundamental and Applied Aspects of Obesity, National Medical Research Center for Therapy and Preventive Medicine, 101990 Moscow, Russia.

Department of Therapy and Preventive Medicine, A.I. Evdokimov Moscow State University of Medicine and Dentistry, 127473 Moscow, Russia.

出版信息

Biomedicines. 2023 Sep 5;11(9):2465. doi: 10.3390/biomedicines11092465.

Abstract

Non-alcoholic fatty liver disease (NAFLD) and arterial hypertension (AH) are widespread noncommunicable diseases in the global population. Since hypertension and NAFLD are diseases associated with metabolic syndrome, they are often comorbid. In fact, many contemporary published studies confirm the association of these diseases with each other, regardless of whether other metabolic factors, such as obesity, dyslipidemia, and type 2 diabetes mellites, are present. This narrative review considers the features of the association between NAFLD and AH, as well as possible pathophysiological mechanisms.

摘要

非酒精性脂肪性肝病(NAFLD)和动脉高血压(AH)是全球人群中广泛存在的非传染性疾病。由于高血压和NAFLD是与代谢综合征相关的疾病,它们常常合并存在。事实上,许多当代发表的研究证实了这些疾病之间的关联,无论是否存在其他代谢因素,如肥胖、血脂异常和2型糖尿病。这篇叙述性综述探讨了NAFLD与AH之间关联的特征以及可能的病理生理机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c56c/10525922/f6b8a62ea2a2/biomedicines-11-02465-g001.jpg

相似文献

1
Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?
Biomedicines. 2023 Sep 5;11(9):2465. doi: 10.3390/biomedicines11092465.
2
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
Gastroenterology. 2022 Sep;163(3):764-774.e1. doi: 10.1053/j.gastro.2022.06.023. Epub 2022 Jul 14.
3
Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
Cureus. 2022 May 30;14(5):e25495. doi: 10.7759/cureus.25495. eCollection 2022 May.
4
Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past.
JHEP Rep. 2021 Feb 26;3(3):100261. doi: 10.1016/j.jhepr.2021.100261. eCollection 2021 Jun.
5
Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.
Perit Dial Int. 2016 Jul-Aug;36(4):427-32. doi: 10.3747/pdi.2014.00223. Epub 2015 Oct 16.
6
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
7
Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
Curr Pharm Des. 2020;26(10):1079-1092. doi: 10.2174/1381612826666200128094231.
10
Nonalcoholic fatty liver disease as a multi-systemic disease.
World J Gastroenterol. 2016 Apr 28;22(16):4079-90. doi: 10.3748/wjg.v22.i16.4079.

引用本文的文献

1
Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis.
World J Cardiol. 2025 Jun 26;17(6):106147. doi: 10.4330/wjc.v17.i6.106147.
2
The relationship between hepatic steatosis index and hypertension: NHANES 2011-2018.
BMC Cardiovasc Disord. 2025 Apr 17;25(1):289. doi: 10.1186/s12872-025-04744-2.
3
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review.
Cardiovasc Diabetol. 2024 Sep 28;23(1):346. doi: 10.1186/s12933-024-02434-5.

本文引用的文献

1
Association between fatty liver index and blood coagulation markers: a population-based study.
Lipids Health Dis. 2023 Jun 29;22(1):83. doi: 10.1186/s12944-023-01854-8.
2
Associations between smoking and alcohol consumption with blood pressure in a middle-aged population.
Tob Induc Dis. 2023 May 18;21:61. doi: 10.18332/tid/162440. eCollection 2023.
3
The shaping of gut immunity in cirrhosis.
Front Immunol. 2023 Apr 14;14:1139554. doi: 10.3389/fimmu.2023.1139554. eCollection 2023.
4
Gut microbiota dependant trimethylamine N-oxide and hypertension.
Front Physiol. 2023 Apr 6;14:1075641. doi: 10.3389/fphys.2023.1075641. eCollection 2023.
6
Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease.
World J Clin Cases. 2023 Feb 26;11(6):1236-1244. doi: 10.12998/wjcc.v11.i6.1236.
7
A major mechanism for immunomodulation: Dietary fibres and acid metabolites.
Semin Immunol. 2023 Mar;66:101737. doi: 10.1016/j.smim.2023.101737. Epub 2023 Feb 27.
8
Association Between Hypertension and New-Onset Non-Alcoholic Fatty Liver Disease in Chinese Non-Obese People: A Longitudinal Cohort Study.
Diabetes Metab Syndr Obes. 2023 Feb 8;16:345-363. doi: 10.2147/DMSO.S396011. eCollection 2023.
9
Gender Differences and Cardiometabolic Risk: The Importance of the Risk Factors.
Int J Mol Sci. 2023 Jan 13;24(2):1588. doi: 10.3390/ijms24021588.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验